According to Lupin, Health Canada has approved the company’s generic version of Boehringer Ingelheim’s Spiriva tiotropium bromide inhalation powder for the treatment of COPD. In the UK, the MHRA approved the company’s Lutio tiotropium DPI for the treatment of COPD in August 2022.
Lupin President, Legal, for Canada, Australia, and Japan, Sofia Mumtaz commented, “This approval of the first generic for tiotropium bromide inhalation powder by Health Canada underscores our commitment to bring affordable options of complex products for patients in Canada, particularly in the respiratory therapeutic area.”
Read the Lupin press release.
